EP
GBT

Elkhorn Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Elkhorn Partners’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,600
Closed -$594K – 50
2022
Q2 		$594K Buy
18,600
+1,650
+10% +$48.3K 0.38% 11
2022
Q1 		$587K Buy
16,950
+2,150
+15% +$64.3K 0.32% 10
2021
Q4 		$433K Buy
14,800
+100
+0.7% +$3.1K 0.24% 13
2021
Q3 		$375K Buy
14,700
+8,400
+133% +$247K 0.23% 14
2021
Q2 		$221K Buy
6,300
+5,150
+448% +$201K 0.14% 19
2021
Q1 		$47K Buy
1,150
+850
+283% +$39.1K 0.03% 30
2020
Q4 		$13K Buy
+300
New +$14.8K 0.01% 32

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Elkhorn Partners's GBT Position: Q3 2022 in Review

Elkhorn Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 18,600 shares — an estimated $594K sold.

Elkhorn Partners first reported a position in GBT in Q4 2020 and held it in 7 quarters. The position peaked at $594K in Q2 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Elkhorn Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Elkhorn Partners sold 18,600 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $594K.
  • Elkhorn Partners first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 7 quarters.
  • Elkhorn Partners's Global Blood Therapeutics, Inc. position peaked at $594K in Q2 2022.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Elkhorn Partners's 13F filing for Q3 2022, filed 14 Nov 2022.